Evidence map›Paper›PMID 35328679›Full record

ArticleInternational journal of molecular sciences2022

Proteomic Assessment of Extracellular Vesicles from Canine Tissue Explants as a Pipeline to Identify Molecular Targets in Osteosarcoma: PSMD14/Rpn11 as a Proof of Principle.

Anita K Luu, Mia Cadieux, Mackenzie Wong, Rachel Macdonald, Robert Jones, Dongsic Choi, Michelle Oblak, Brigitte Brisson, Scott Sauer, James Chafitz and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Prospects and challenges of tissue-derived extracellular vesicles.Molecular therapy : the journal of the American Society of Gene Therapy · 2024
    Review
  4. Article
  5. Review
  6. Article
  7. Molecular and Translational Research on Bone Tumors.International journal of molecular sciences · 2023
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Anita K LuuDepartment of Biomedical Sciences, Ontario Veterinary College, University of Guelph, Guelph, ON N1G 2W1, Canada.
Mia CadieuxDepartment of Biomedical Sciences, Ontario Veterinary College, University of Guelph, Guelph, ON N1G 2W1, Canada.ORCID 0000-0001-6871-0082
Mackenzie WongDepartment of Biomedical Sciences, Ontario Veterinary College, University of Guelph, Guelph, ON N1G 2W1, Canada.
Rachel MacdonaldDepartment of Biomedical Sciences, Ontario Veterinary College, University of Guelph, Guelph, ON N1G 2W1, Canada.
Robert JonesDepartment of Animal Biosciences, Ontario Agricultural College, University of Guelph, Guelph, ON N1G 2W1, Canada.
Dongsic ChoiDepartment of Biochemistry, College of Medicine, Soonchunhyang University, Cheonan 31151, Korea.ORCID 0000-0002-2516-5616
Michelle OblakDepartment of Clinical Studies, Ontario Veterinary College, University of Guelph, Guelph, ON N1G 2W1, Canada.ORCID 0000-0001-8489-4643
Brigitte BrissonDepartment of Clinical Studies, Ontario Veterinary College, University of Guelph, Guelph, ON N1G 2W1, Canada.
Scott SauerVuja De Sciences, Inc., Natick, MA 01760, USA.
James ChafitzSBH Sciences, Natick, MA 01760, USA.
David WarshawskyVuja De Sciences, Inc., Natick, MA 01760, USA.
Geoffrey A WoodDepartment of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, ON N1G 2W1, Canada.ORCID 0000-0003-1756-8607
Alicia M Viloria-PetitDepartment of Biomedical Sciences, Ontario Veterinary College, University of Guelph, Guelph, ON N1G 2W1, Canada.
University of Guelph · CASoonchunhyang University · KR

Funding

OVC Pet Trust 053666
6 · The paper itself

Abstract

Osteosarcoma (OS) is a highly malignant bone tumour that has seen little improvement in treatment modalities in the past 30 years. Understanding what molecules contribute to OS biology could aid in the discovery of novel therapies. Extracellular vesicles (EVs) serve as a mode of cell-to-cell communication and have the potential to uncover novel protein signatures. In our research, we developed a novel pipeline to isolate, characterize, and profile EVs from normal bone and osteosarcoma tissue explants from canine OS patients. Proteomic analysis of vesicle preparations revealed a protein signature related to protein metabolism. One molecule of interest, PSMD14/Rpn11, was explored further given its prognostic potential in human and canine OS, and its targetability with the drug capzimin. In vitro experiments demonstrated that capzimin induces apoptosis and reduces clonogenic survival, proliferation, and migration in two metastatic canine OS cell lines. Capzimin also reduces the viability of metastatic human OS cells cultured under 3D conditions that mimic the growth of OS cells at secondary sites. This unique pipeline can improve our understanding of OS biology and identify new prognostic markers and molecular targets for both canine and human OS patients.

Indexed as

Bone NeoplasmsExtracellular VesiclesOsteosarcomaAnimalsCell Line, TumorCell ProliferationDogsHumansProteasome Endopeptidase ComplexProteomicsTrans-ActivatorsProteasome Endopeptidase ComplexPSMD14 protein, humanTrans-Activatorsbiomarker discoveryextracellular vesiclesmolecular targetsosteosarcomatissue explants

Identifiers

PMID35328679
PMCPMC8953151
OpenAlexW4220660884

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.